search
Back to results

Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects

Primary Purpose

Healthy, Prediabetic State

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Collagen hydrolysate
Placebo
Sponsored by
Rousselot BVBA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Healthy focused on measuring collagen peptides, blood sugar modifying

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Main Inclusion Criteria: Prediabetic subjects: Male and female subjects with prediabetic HbA1c values between 5.7% and 6.4% and/or fasting glucose ≥ 100 mg/dL and ≤ 125 mg/dL (in venous plasma) (twice confirmed at two independent days if HbA1c is < 5.7%) or Healthy normo-glycaemic subjects: fasting glucose <100 mg/dL and HbA1c is < 5.7% Age: 18-70 years Body mass index 19-35 kg/m2 Current Non-smoker Signed informed consent form No changes in food habits or physical activity 3 months prior to screening and during the study If applicable, stable intake of chronic medication of at least 4 weeks Main Exclusion Criteria: Subjects with diagnosed Type 2 Diabetes mellitus with medical treatment Presence of disease or drug(s) influencing digestion (incl. recent intake of antibiotics) and absorption of nutrients Intake of medications known to affect glucose tolerance, e.g., diabetic medication, SGLT-2 inhibitors, GLP-1 receptor agonists, steroids, protease inhibitors or antipsychotics Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the Investigator's opinion would impact patient safety Severe liver or renal disease or laboratory evidence of hepatic dysfunction (i.e. alkaline phosphatase, ALT, AST >3 x ULN) Known inflammatory or malignant gastrointestinal diseases (i.e. colitis ulcerosa, Morbus Crohn, celiac disease, malignant diseases e.g. colon-cancer, rectum cancer, pancreatitis) Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs Intake of food supplements known to affect glucose tolerance, e.g., cinnamon capsules, conjugated linoleic acids Drug-, alcohol- and medication abuses Pregnant or breast-feeding women

Sites / Locations

  • BioTeSys GmbHRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Collagen hydrolysate dose 1

Collagen hydrolysate dose 2

Placebo

Arm Description

Source: porcine; standardized to 10 g provided as single dose. Orally applied in flavoured water.

Source: porcine; standardized to 5 g provided as single dose. Orally applied in flavoured water.

Flavoured water

Outcomes

Primary Outcome Measures

Glucose iAUC
Area under the curve (AUC) calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-180minutes)

Secondary Outcome Measures

Glucose iAUC
Area under the curve calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-240minutes)
Glucose Cmax
Maximum blood glucose concentration (Cmax)
Delta Cmax
Maximum increase of blood glucose concentration
Tmax
Time to reach maximum blood glucose concentration (Tmax)
T baseline
First time to reach baseline again after increase or decrease in blood glucose
Matsuda-Index
Determination of Insulin sensitivity
Glucose dip
maximum dip below baseline and time point of glucose dip
Insulin iAUC
Area under the curve calculated as the incremental area under the insulin curve
GLP-1
Incretin response (Glucagon-like Peptide-1)
Satiety assessment
Visual analog scale (VAS) Scale (0: not at all 100: extremely)

Full Information

First Posted
May 24, 2023
Last Updated
June 15, 2023
Sponsor
Rousselot BVBA
Collaborators
BioTeSys GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT05887791
Brief Title
Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects
Official Title
Clinical Study to Assess the Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects: Randomized, Double-blind, Placebo-controlled, Cross-over Study With Different Dosages
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 15, 2023 (Actual)
Primary Completion Date
December 23, 2023 (Anticipated)
Study Completion Date
December 23, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rousselot BVBA
Collaborators
BioTeSys GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To investigate the effect of two different dosages collagen hydrolysate (CH) on postprandial blood glucose and insulin profile in prediabetic and normo-glycaemic subjects.This will be investigated in a cross-over randomized double-blind placebo controlled study design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy, Prediabetic State
Keywords
collagen peptides, blood sugar modifying

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Collagen hydrolysate dose 1
Arm Type
Experimental
Arm Description
Source: porcine; standardized to 10 g provided as single dose. Orally applied in flavoured water.
Arm Title
Collagen hydrolysate dose 2
Arm Type
Experimental
Arm Description
Source: porcine; standardized to 5 g provided as single dose. Orally applied in flavoured water.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Flavoured water
Intervention Type
Dietary Supplement
Intervention Name(s)
Collagen hydrolysate
Intervention Description
Single dose
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Single dose
Primary Outcome Measure Information:
Title
Glucose iAUC
Description
Area under the curve (AUC) calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-180minutes)
Time Frame
0-180 minutes postprandially
Secondary Outcome Measure Information:
Title
Glucose iAUC
Description
Area under the curve calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-240minutes)
Time Frame
0-240 minutes postprandially
Title
Glucose Cmax
Description
Maximum blood glucose concentration (Cmax)
Time Frame
0-180 minutes postprandially
Title
Delta Cmax
Description
Maximum increase of blood glucose concentration
Time Frame
0-180 minutes postprandially
Title
Tmax
Description
Time to reach maximum blood glucose concentration (Tmax)
Time Frame
0-180 minutes postprandially
Title
T baseline
Description
First time to reach baseline again after increase or decrease in blood glucose
Time Frame
0-240 minutes postprandially
Title
Matsuda-Index
Description
Determination of Insulin sensitivity
Time Frame
0-120 minutes postprandially
Title
Glucose dip
Description
maximum dip below baseline and time point of glucose dip
Time Frame
0-240 minutes postprandially
Title
Insulin iAUC
Description
Area under the curve calculated as the incremental area under the insulin curve
Time Frame
up to 0-240 minutes postprandially
Title
GLP-1
Description
Incretin response (Glucagon-like Peptide-1)
Time Frame
0-120 minutes postprandially
Title
Satiety assessment
Description
Visual analog scale (VAS) Scale (0: not at all 100: extremely)
Time Frame
0-240 minutes postprandially
Other Pre-specified Outcome Measures:
Title
Gastrointestinal hormones
Description
Peptid YY (PYY), Ghrelin, Cholecystokinin (CCK), Leptin
Time Frame
0-120 minutes postprandially
Title
Amino acids
Description
Concentration-time curve of amino acids in plasma together with small molecular weight peptides
Time Frame
0-240 minutes postprandially

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Main Inclusion Criteria: Prediabetic subjects: Male and female subjects with prediabetic HbA1c values between 5.7% and 6.4% and/or fasting glucose ≥ 100 mg/dL and ≤ 125 mg/dL (in venous plasma) (twice confirmed at two independent days if HbA1c is < 5.7%) or Healthy normo-glycaemic subjects: fasting glucose <100 mg/dL and HbA1c is < 5.7% Age: 18-70 years Body mass index 19-35 kg/m2 Current Non-smoker Signed informed consent form No changes in food habits or physical activity 3 months prior to screening and during the study If applicable, stable intake of chronic medication of at least 4 weeks Main Exclusion Criteria: Subjects with diagnosed Type 2 Diabetes mellitus with medical treatment Presence of disease or drug(s) influencing digestion (incl. recent intake of antibiotics) and absorption of nutrients Intake of medications known to affect glucose tolerance, e.g., diabetic medication, SGLT-2 inhibitors, GLP-1 receptor agonists, steroids, protease inhibitors or antipsychotics Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the Investigator's opinion would impact patient safety Severe liver or renal disease or laboratory evidence of hepatic dysfunction (i.e. alkaline phosphatase, ALT, AST >3 x ULN) Known inflammatory or malignant gastrointestinal diseases (i.e. colitis ulcerosa, Morbus Crohn, celiac disease, malignant diseases e.g. colon-cancer, rectum cancer, pancreatitis) Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs Intake of food supplements known to affect glucose tolerance, e.g., cinnamon capsules, conjugated linoleic acids Drug-, alcohol- and medication abuses Pregnant or breast-feeding women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicoletta Virgilio, PhD
Organizational Affiliation
Rousselot BV
Official's Role
Study Director
Facility Information:
Facility Name
BioTeSys GmbH
City
Esslingen
ZIP/Postal Code
73728
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacqueline Autenrieth
Phone
0711/31057138
Email
blutzucker@biotesys.de
First Name & Middle Initial & Last Name & Degree
Daniel Menzel, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects

We'll reach out to this number within 24 hrs